First Wave BioPharma, Inc. – NASDAQ:FWBI

First Wave BioPharma stock price today

$2.96
Financial Health
0
1
2
3
4
5
6
7
8
9

First Wave BioPharma stock price monthly change

-27.63%
month

First Wave BioPharma stock price quarterly change

-46.08%
quarter

First Wave BioPharma stock price yearly change

+12.12%
year

First Wave BioPharma key metrics

Market Cap
5.99M
Enterprise value
1.17M
P/E
-0.1
EV/Sales
N/A
EV/EBITDA
-0.08
Price/Sales
N/A
Price/Book
0.60
PEG ratio
N/A
EPS
-45.48
Revenue
N/A
EBITDA
-20.90M
Income
-6.15M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

First Wave BioPharma stock price history

First Wave BioPharma stock forecast

First Wave BioPharma financial statements

First Wave BioPharma, Inc. (NASDAQ:FWBI): Profit margin
Jun 2023 0 -4.18M
Sep 2023 0 -3.43M
Dec 2023 138.76K -4.10M -2955.25%
Mar 2024 0 5.56M
First Wave BioPharma, Inc. (NASDAQ:FWBI): Analyst Estimates
2025 16.47M -32.12M -195%
2026 22.26M -42.26M -189.84%
2027 27.50M -733.22K -2.67%
2028 58.14M 154.71K 0.27%
  • Analysts Price target

  • Financials & Ratios estimates

First Wave BioPharma, Inc. (NASDAQ:FWBI): Earnings per share (EPS)
2022-11-14 -21.07 18.2
2023-03-20 -30.87125 -9.47
First Wave BioPharma, Inc. (NASDAQ:FWBI): Debt to assets
Jun 2023 4327871 3.44M 79.62%
Sep 2023 5927269 2.64M 44.68%
Dec 2023 6883195 3.28M 47.66%
Mar 2024 91133902 13.26M 14.56%
First Wave BioPharma, Inc. (NASDAQ:FWBI): Cash Flow
Jun 2023 -2.76M 0 1.93M
Sep 2023 -3.33M 0 5.38M
Dec 2023 -3.43M -500K 4.35M
Mar 2024 -3.74M 88.16K 3.37M

First Wave BioPharma alternative data

First Wave BioPharma, Inc. (NASDAQ:FWBI): Employee count
Aug 2023 10
Sep 2023 10
Oct 2023 10
Nov 2023 10
Dec 2023 10
Jan 2024 10
Feb 2024 10
Mar 2024 10
Apr 2024 10
May 2024 9
Jun 2024 9
Jul 2024 9

First Wave BioPharma other data

21.75% -7.72%
of FWBI is owned by hedge funds
22.31K -46.13K
shares is hold by hedge funds

First Wave BioPharma, Inc. (NASDAQ:FWBI): Insider trades (number of shares)
Period Buy Sel
Jul 2023 0 5326
Aug 2023 0 6053
Sep 2023 0 10
Oct 2023 0 4440
Jan 2024 0 264
Mar 2024 0 3007
Apr 2024 0 249
Transaction Date Insider Security Shares Price per share Total value Source
Sale
ROMANO SARAH officer: Chief Fi.. Common Stock 75 $4.23 $317
Sale
SAPIRSTEIN JAMES director, officer: Chairman and..
Common Stock 174 $4.23 $736
Sale
SAPIRSTEIN JAMES director, officer: Chairman and..
Common Stock 1,887 $4.96 $9,360
Sale
ROMANO SARAH officer: Chief Fi.. Common Stock 1,120 $4.96 $5,555
Sale
ROMANO SARAH officer: Chief Fi.. Common Stock 98 $4.2 $412
Sale
SAPIRSTEIN JAMES director, officer: Chairman, Pr..
Common Stock 166 $4.2 $697
Sale
ROMANO SARAH officer: Chief Fi.. Common Stock 1,676 $0.29 $486
Sale
SAPIRSTEIN JAMES director, officer: President an..
Common Stock 2,764 $0.29 $802
Sale
CASAMENTO CHARLES J director
Common Stock 10 $0.43 $4
Sale
CASAMENTO CHARLES J director
Common Stock 6,053 $0.3 $1,816
Friday, 10 May 2024
globenewswire.com
Thursday, 9 May 2024
globenewswire.com
Wednesday, 24 April 2024
globenewswire.com
Wednesday, 17 April 2024
GlobeNewsWire
Friday, 5 April 2024
Zacks Investment Research
Wednesday, 27 March 2024
Zacks Investment Research
Thursday, 14 March 2024
InvestorPlace
Tuesday, 13 February 2024
GlobeNewsWire
Tuesday, 23 January 2024
GlobeNewsWire
Wednesday, 27 December 2023
Market Watch
Tuesday, 3 October 2023
GlobeNewsWire
Friday, 15 September 2023
GlobeNewsWire
Thursday, 14 September 2023
Market Watch
Friday, 14 July 2023
Zacks Investment Research
Wednesday, 14 June 2023
Zacks Investment Research
Monday, 15 May 2023
GlobeNewsWire
Monday, 30 January 2023
GlobeNewsWire
Wednesday, 25 January 2023
InvestorPlace
Tuesday, 24 January 2023
GlobeNewsWire
Monday, 16 January 2023
Zacks Investment Research
Wednesday, 28 September 2022
GlobeNewsWire
Monday, 29 August 2022
GlobeNewsWire
Monday, 2 May 2022
Benzinga
Thursday, 31 March 2022
PennyStocks
  • What's the price of First Wave BioPharma stock today?

    One share of First Wave BioPharma stock can currently be purchased for approximately $2.96.

  • When is First Wave BioPharma's next earnings date?

    Unfortunately, First Wave BioPharma's (FWBI) next earnings date is currently unknown.

  • Does First Wave BioPharma pay dividends?

    No, First Wave BioPharma does not pay dividends.

  • How much money does First Wave BioPharma make?

    First Wave BioPharma has a market capitalization of 5.99M. First Wave BioPharma made a loss 15.79M US dollars in net income (profit) last year or -$9.47 on an earnings per share basis.

  • What is First Wave BioPharma's stock symbol?

    First Wave BioPharma, Inc. is traded on the NASDAQ under the ticker symbol "FWBI".

  • What is First Wave BioPharma's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of First Wave BioPharma?

    Shares of First Wave BioPharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • How many employees does First Wave BioPharma have?

    As Jul 2024, First Wave BioPharma employs 9 workers, which is 10% less then previous quarter.

  • When First Wave BioPharma went public?

    First Wave BioPharma, Inc. is publicly traded company for more then 8 years since IPO on 11 Oct 2016.

  • What is First Wave BioPharma's official website?

    The official website for First Wave BioPharma is firstwavebio.com.

  • Where are First Wave BioPharma's headquarters?

    First Wave BioPharma is headquartered at 777 Yamato Road, Boca Raton, FL.

  • How can i contact First Wave BioPharma?

    First Wave BioPharma's mailing address is 777 Yamato Road, Boca Raton, FL and company can be reached via phone at +56 15897020.

First Wave BioPharma company profile:

First Wave BioPharma, Inc.

firstwavebio.com
Exchange:

NASDAQ

Full time employees:

9

Industry:

Biotechnology

Sector:

Healthcare

First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties; and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis. It also develops FW-CD, which has completed Phase I clinical trials for Crohn's disease; and adrulipase, an oral, non-systemic, and biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.

777 Yamato Road
Boca Raton, FL 33431

CIK: 0001604191
ISIN: US33749P4081
CUSIP: 33749P101